Zhaopei F. Liu
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.
Journal: Journal for immunotherapy of cancer
Published: May 05, 2026
Delayed Partial Nephrectomy After Renal Cryoablation: Whole-Lesion Histology and Clinical Course of a Single Case.
Journal: Journal of clinical medicine
Published: April 07, 2026
Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.
Journal: Cancer
Published: February 10, 2026
Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression.
Journal: British journal of cancer
Published: October 16, 2025
TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.
Journal: British journal of cancer
Published: July 24, 2025
ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2025
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.
Journal: Journal for immunotherapy of cancer
Published: December 13, 2024
CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer.
Journal: Frontiers in oncology
Published: September 19, 2024
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma.
Journal: BMJ oncology
Published: August 24, 2024
Last Updated: 09/26/2026